Cargando…
Lanthanum-based metal organic framework (La-MOF) use of 3,4-dihydroxycinnamic acid as drug delivery system linkers in human breast cancer therapy
Metal organic frameworks (MOFs) have received a lot of attention in the research community due to their unique physical properties, which make them ideal materials for targeted drug delivery systems. In this paper, we describe the synthesis of a non-toxic La-based MOF with 3,4-dihydroxycinnamic acid...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655864/ https://www.ncbi.nlm.nih.gov/pubmed/36371207 http://dx.doi.org/10.1186/s13065-022-00886-y |
_version_ | 1784829291560697856 |
---|---|
author | Safinejad, Moosareza Rigi, Amir Zeraati, Malihe Heidary, Zohreh Jahani, Shohreh Chauhan, Narendra Pal Singh Sargazi, Ghasem |
author_facet | Safinejad, Moosareza Rigi, Amir Zeraati, Malihe Heidary, Zohreh Jahani, Shohreh Chauhan, Narendra Pal Singh Sargazi, Ghasem |
author_sort | Safinejad, Moosareza |
collection | PubMed |
description | Metal organic frameworks (MOFs) have received a lot of attention in the research community due to their unique physical properties, which make them ideal materials for targeted drug delivery systems. In this paper, we describe the synthesis of a non-toxic La-based MOF with 3,4-dihydroxycinnamic acid (3,4-DHCA) as a linker. Scanning electron microscopy (SEM), transmission electron microscopy (TEM), energy dispersive spectroscopy (EDS), fourier transform infrared (FTIR) spectroscopy, thermogravimetric analysis (TGA), nitrogen adsorption–desorption measurements, and X-ray powder diffraction (XRD) have all been used to characterize it thoroughly. The La-based MOF showed good biocompatibility with the human breast cancer cell line MDA-MB-468. The ability of 3,4-DHCA to treat MDA-MB-468 cells was confirmed by 40.35% cell viability with La-based MOF. Based on the findings, La-based MOF can be recommended as a promising candidate for anticancer delivery. |
format | Online Article Text |
id | pubmed-9655864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-96558642022-11-15 Lanthanum-based metal organic framework (La-MOF) use of 3,4-dihydroxycinnamic acid as drug delivery system linkers in human breast cancer therapy Safinejad, Moosareza Rigi, Amir Zeraati, Malihe Heidary, Zohreh Jahani, Shohreh Chauhan, Narendra Pal Singh Sargazi, Ghasem BMC Chem Research Metal organic frameworks (MOFs) have received a lot of attention in the research community due to their unique physical properties, which make them ideal materials for targeted drug delivery systems. In this paper, we describe the synthesis of a non-toxic La-based MOF with 3,4-dihydroxycinnamic acid (3,4-DHCA) as a linker. Scanning electron microscopy (SEM), transmission electron microscopy (TEM), energy dispersive spectroscopy (EDS), fourier transform infrared (FTIR) spectroscopy, thermogravimetric analysis (TGA), nitrogen adsorption–desorption measurements, and X-ray powder diffraction (XRD) have all been used to characterize it thoroughly. The La-based MOF showed good biocompatibility with the human breast cancer cell line MDA-MB-468. The ability of 3,4-DHCA to treat MDA-MB-468 cells was confirmed by 40.35% cell viability with La-based MOF. Based on the findings, La-based MOF can be recommended as a promising candidate for anticancer delivery. Springer International Publishing 2022-11-12 /pmc/articles/PMC9655864/ /pubmed/36371207 http://dx.doi.org/10.1186/s13065-022-00886-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Safinejad, Moosareza Rigi, Amir Zeraati, Malihe Heidary, Zohreh Jahani, Shohreh Chauhan, Narendra Pal Singh Sargazi, Ghasem Lanthanum-based metal organic framework (La-MOF) use of 3,4-dihydroxycinnamic acid as drug delivery system linkers in human breast cancer therapy |
title | Lanthanum-based metal organic framework (La-MOF) use of 3,4-dihydroxycinnamic acid as drug delivery system linkers in human breast cancer therapy |
title_full | Lanthanum-based metal organic framework (La-MOF) use of 3,4-dihydroxycinnamic acid as drug delivery system linkers in human breast cancer therapy |
title_fullStr | Lanthanum-based metal organic framework (La-MOF) use of 3,4-dihydroxycinnamic acid as drug delivery system linkers in human breast cancer therapy |
title_full_unstemmed | Lanthanum-based metal organic framework (La-MOF) use of 3,4-dihydroxycinnamic acid as drug delivery system linkers in human breast cancer therapy |
title_short | Lanthanum-based metal organic framework (La-MOF) use of 3,4-dihydroxycinnamic acid as drug delivery system linkers in human breast cancer therapy |
title_sort | lanthanum-based metal organic framework (la-mof) use of 3,4-dihydroxycinnamic acid as drug delivery system linkers in human breast cancer therapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655864/ https://www.ncbi.nlm.nih.gov/pubmed/36371207 http://dx.doi.org/10.1186/s13065-022-00886-y |
work_keys_str_mv | AT safinejadmoosareza lanthanumbasedmetalorganicframeworklamofuseof34dihydroxycinnamicacidasdrugdeliverysystemlinkersinhumanbreastcancertherapy AT rigiamir lanthanumbasedmetalorganicframeworklamofuseof34dihydroxycinnamicacidasdrugdeliverysystemlinkersinhumanbreastcancertherapy AT zeraatimalihe lanthanumbasedmetalorganicframeworklamofuseof34dihydroxycinnamicacidasdrugdeliverysystemlinkersinhumanbreastcancertherapy AT heidaryzohreh lanthanumbasedmetalorganicframeworklamofuseof34dihydroxycinnamicacidasdrugdeliverysystemlinkersinhumanbreastcancertherapy AT jahanishohreh lanthanumbasedmetalorganicframeworklamofuseof34dihydroxycinnamicacidasdrugdeliverysystemlinkersinhumanbreastcancertherapy AT chauhannarendrapalsingh lanthanumbasedmetalorganicframeworklamofuseof34dihydroxycinnamicacidasdrugdeliverysystemlinkersinhumanbreastcancertherapy AT sargazighasem lanthanumbasedmetalorganicframeworklamofuseof34dihydroxycinnamicacidasdrugdeliverysystemlinkersinhumanbreastcancertherapy |